Johannesburg-based pharmaceutical giant Aspen Pharmacare announced December 29th the sale of its Asia-Pacific business to Australian private equity firm BGH Capital for an estimated €1.3 billion. The move signals a significant restructuring effort for Aspen as it works to address recent financial headwinds and prioritize key growth areas. This transaction,encompassing operations in Australia,New Zealand,and several key Asian markets,comes amid a challenging period for the company,which recently reported a net annual loss [[3]].
Johannesburg-based pharmaceutical company Aspen Pharmacare has agreed to sell its Asia-Pacific business to Australian private equity firm BGH Capital for an estimated €1.3 billion (26.4 billion South African Rand). The deal, announced December 29, marks a significant step in Aspen’s efforts to restructure its finances and refocus its strategic priorities.
Optimizing Group Financial Structure
The transaction encompasses 100% of Aspen’s operations in Australia, New Zealand, and several key Asia-Pacific markets including Hong Kong, Malaysia, Taiwan, and the Philippines. Intellectual property rights marketed within the region are also included in the sale, with the exception of Aspen’s Chinese operations. According to filings, the divested portfolio represented 18% of the group’s total revenue and 26% of its current operating profit for the fiscal year ending 2025.
Aspen stated it did not initiate a formal sales process, but rather evaluated an unsolicited offer from BGH Capital. Following this assessment, the boards of directors negotiated a deal representing “a multiple of approximately 11 times the reported enterprise value to normalized EBITDA for the fiscal year 2025.”
“This transaction aligns with our strategic objectives and represents a compelling proposition for the group and its shareholders,” said Aspen CEO Stephen Saad. “It allows us to unlock value within Aspen APAC, improve our balance sheet flexibility, and strengthen the foundations necessary to execute our growth strategy.”
Upon completion of the deal, Aspen intends to use the proceeds to reduce its debt and optimize its financial structure, lowering financing costs and simplifying its lender base. While the total debt amount was not disclosed, the company secured a €500 million loan in September 2024 from the SFI, Germany’s DEG, and the U.S. DFC to support the production and distribution of medicines and vaccines in Africa.
Ongoing Reorganization
The announced transaction comes as Aspen navigates a challenging period. The group reported a net annual loss of 1.1 billion South African Rand (approximately €55 million) for the fiscal year ended June 2025, a reversal from the 4.4 billion Rand profit recorded the previous year. This shift underscores the competitive pressures facing pharmaceutical companies globally.
The decline in profitability was attributed, in part, to the loss of a major contract in the manufacturing of messenger RNA products.
To address these challenges, Aspen is refocusing its industrial operations on higher-growth segments. The company is betting on increased insulin production in South Africa and the phased integration of GLP-1 type medications for the treatment of diabetes and obesity – a rapidly expanding global market. In October, the company received regulatory approval from South African authorities to market Mounjaro, a drug developed by Eli Lilly.
More recently, in November, Aspen reaffirmed its commitment to the diabetes market, highlighting the increasing prevalence of the disease within South African and African healthcare systems. The company also emphasized the strategic importance of treatments now recognized by the World Health Organization (WHO), which added GLP-1 agonists to its list of essential medicines in 2025 for the treatment of type 2 diabetes. According to the WHO, approximately 6% of the global population (420 million people) currently lives with type 1 or type 2 diabetes, a figure projected to exceed half a billion by 2030.
